论文部分内容阅读
目的观察非小细胞肺癌骨转移疼痛经化疗和复方苦参注射液联合治疗的临床效果。方法 96例非小细胞肺癌骨转移疼痛患者,根据其入院顺序随机分为观察组和对照组,各48例。对照组行化疗治疗,观察组经化疗联合复方苦参注射液治疗。观察两组患者的临床治疗效果,视觉模拟评分(VAS评分)和毒副作用的发生情况。结果 1观察组总有效率为62.50%,显著高于对照组的41.67%,差异有统计学意义(P<0.05)。2治疗前,对照组患者的VAS评分为(7.46±0.43)分,观察组为(7.40±0.47)分,比较差异无统计学意义(P>0.05)。治疗后,对照组为(2.99±0.34)分,观察组为(1.94±0.27)分,与治疗前相比,两组均有显著改善(P<0.05),且观察组显著优于对照组(P<0.05)。结论非小细胞肺癌骨转移疼痛经化疗和复方苦参注射液联合治疗具有显著效果,可以有效提高治疗效果,缓解疼痛,控制毒副反应的发生,安全有效,临床应用价值较高。
Objective To observe the clinical effect of combined treatment of chemotherapy and compound Kushen injection on bone metastasis pain of non-small cell lung cancer. Methods 96 patients with bone metastases of non-small cell lung cancer patients were randomly divided into observation group and control group according to their order of admission, 48 cases each. The control group was treated with chemotherapy and the observation group was treated with chemotherapy combined with Compound Kushen Injection. The clinical efficacy, visual analogue scale (VAS score) and the incidence of side effects were observed in both groups. Results 1 The total effective rate of the observation group was 62.50%, which was significantly higher than that of the control group (41.67%), the difference was statistically significant (P <0.05). Before treatment, the VAS score of the control group was (7.46 ± 0.43) points, and the observation group was (7.40 ± 0.47) points, the difference was not statistically significant (P> 0.05). After treatment, the control group was (2.99 ± 0.34) points and the observation group was (1.94 ± 0.27) points, both groups were significantly improved (P <0.05), and the observation group was significantly better than the control group P <0.05). Conclusion Bone metastasis of non-small cell lung cancer by chemotherapy and compound Kushen injection has a significant effect, which can effectively improve the treatment effect, relieve pain and control the occurrence of toxic and side effects, which is safe and effective and has high clinical value.